Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Genzyme Corporation
483
•Genzyme Corporation•September 4, 2020

FDA 483 - Genzyme Corporation - September 04, 2020

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

Genzyme Corporation, a drug substance manufacturer in Framingham, MA, was cited for two observations during an FDA inspection. The inspection revealed inadequate maintenance of facilities and equipment, including issues with sterilization equipment, air filters, and diffusers. Additionally, the QC Microbiology Laboratory had uncertified equipment and failed to conduct logbook reviews according to established procedures.

Company
Genzyme Corporation
Inspection Date
September 4, 2020
Product Type
Drugs
Office
Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
People
  • Ying-Xin Fan (issuing_officer)
  • Wayne E. Seifert (Senior Regulatory Specialist)
Open in Dashboard

ID · 92fb5a72-64b2-4547-a360-5fbd53dbb20b

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.